ERBB2 and neoplasm: For instance, a preclinical study evaluated the intravesical administration of the HER2-targeted antibody-drug conjugate RC48-ADC, demonstrating potent antitumor activity dependent on HER2 expression, significant tumor burden reduction in an orthotopic model, and a favorable safety profile 11.